title: Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.
abstract: Prostate cancer is the second leading cause of cancer-related death in men in most Western countries. In this report, we present 2 cases of metastatic castration-resistant prostate cancer and chronic kidney disease. Both patients underwent and developed clinical resistance to androgen-deprivation therapy. Subsequently, the patients were treated with the conventional chemotherapeutic approach, which resulted in the worsening of renal function and performance status. Therefore, we opted for treatment with abiraterone acetate, and the patients exhibited improvements in renal function with good response of the disease.
authors.affiliation: From the Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Roma (EF); Pharmacology Unit (AIF); and Medical Oncology Unit, University of Siena, Siena, Italy (RP, LL, GR).
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.forename: Anna Ida
authors.initials: AI
authors.lastname: Fiaschi
authors.forename: Letizia
authors.initials: L
authors.lastname: Laera
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy*; D000368:Aged; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; C089740:abiraterone